Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × OTHER_GOV × daratumumab × Clear all

Phase

Status

Sponsor Class

OTHER 84 INDUSTRY 20 NETWORK 5 NIH 3 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms, Plasma Cell 1 Multiple Myeloma 1

Interventions

Capecitabine 27 Cisplatin 23 tislelizumab 22 Oxaliplatin 22 Gemcitabine 22 apatinib 21 Paclitaxel 18 Irinotecan 17 Carboplatin 17 Docetaxel 15 Bevacizumab 15 Fluorouracil 12 Drug Therapy 12 pembrolizumab 10 camrelizumab 10 Cyclophosphamide 10 Radiation 9 Vinorelbine 8 S 1 (combination) 8 Cetuximab 8 Rituximab 7 Erlotinib Hydrochloride 7 Leucovorin 6 Gefitinib 6 Albumin-Bound Paclitaxel 6 toripalimab 5 sintilimab 5 pyrotinib 5 fludarabine 5 Trastuzumab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04065789 2022-01-27

KyDaR

Tel-Aviv Sourasky Medical Center

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡